Improving cancer treatment decisions using advanced imaging techniques.
Development and Pre-Clinical Validation of Quantitative Imaging of Cell State Kinetics (QuICK) for Functional Precision Oncology
This study is testing a new way to see how melanoma tumor cells react to different treatments, helping doctors make more personalized choices for patients by closely watching how each cell behaves over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10928191 on NIH RePORTER |
What this research studies
This research focuses on developing a new imaging method called QuICK that allows for the detailed observation of tumor cell behavior in response to different cancer treatments. By analyzing how tumor cells react to therapies at a single-cell level, the goal is to provide personalized insights that can guide treatment choices for patients, particularly those with melanoma. The approach aims to retain the diversity of tumor cells and monitor their responses over time, which is crucial for understanding treatment resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients, especially those with the BRAFV600E mutation, who are facing treatment decisions between immune checkpoint inhibitors and targeted therapies.
Not a fit: Patients with cancers other than melanoma or those who do not have the BRAFV600E mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatment strategies, improving outcomes for patients.
How similar studies have performed: Previous research in functional precision oncology has shown promise in improving treatment outcomes, suggesting that this approach could be effective.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Zangle, Thomas Andrew — University of Utah
- Study coordinator: Zangle, Thomas Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.